New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
09:11 EDTRAREUltragenyx reports Q1 EPS (85c), consensus (37c)
Total operating expenses for Q1 were $10.3M compared with $6.7M for the same period in 2013. The increase in total operating expenses is due to the expansion and advancement of Ultragenyx's clinical development pipeline, including the initiation of clinical studies for triheptanoin and recombinant human beta-glucuronidase, as well as increased headcount.
News For RARE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
09:04 EDTRAREUltragenyx granted EU orphan designation for KRN23
Subscribe for More Information
October 27, 2014
12:22 EDTRAREUltragenyx management to meet with SunTrust
Subscribe for More Information
09:10 EDTRAREUltragenyx granted orphan drug designation for triheptanoin
Subscribe for More Information
October 22, 2014
09:04 EDTRAREUltragenyx triheptanoin granted FDA orphan designation
Subscribe for More Information
October 21, 2014
09:48 EDTRAREShire could target BioMarin, TheStreet's Feuerstein says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use